You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Recombinant Fc fusions for treatment of uropathogenic E. coli

    SBC: Planet Biotechnology Incorporated            Topic: 300

    Urinary tract infections (UTIs) are among the most common bacterial infections, affecting 150 million people worldwide each year. In the USA, community-acquired UTIs account for about 11 million cases each year that cost the U.S. public health budget $5 billion annually. Uropathogenic Escherichia coli (UPEC) accounts for up to 80% of UTIs. While UTIs are currently treated with antibiotics, the fre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Caregiver Application and AI-Enabled Intelligent Assistant to Support Families and Formal Care Providers in Caring for Persons with Alzheimer's Disease and Related Dementias

    SBC: Whiplash Technology, Inc.            Topic: NIA

    PROJECT ABSTRACT Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can address the specific care needs of each AD patient. To address this critical gap, we developed CareVirtue, an innovative web/mobile application for family ca ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Prevention of White Matter Injury in Premature Infants

    SBC: Medosome Biotec, LLC            Topic: NICHD

    ABSTRACTUp to 30% of low birth weight preterm infants manifest some form of periventricular white matter injury (PWMI) making it the most common form of brain injury affecting premature infants. PWMI is associated with significant morbidity, as affected individuals may have profound intellectual impairment and cerebral palsy. Highlighting the magnitude of PWMI, each year more than 400,000 infants ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical feasibility of a non-invasive, low-cost wearable for measuring air trapping in COPD

    SBC: SAMAY, INC.            Topic: NHLBI

    ABSTRACTChronic Obstructive Pulmonary Disease (COPD) is the third leading cause of hospitalization in the US. Exacerbations - a worsening or “flare up” of symptoms - cause most COPD hospitalizations. Since most exacerbations can be treated with changes of inhalers and/or oral medications, at-home detection of lung function deterioration may facilitate earlier intervention and help delay or pre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A novel role for Reelin therapeutics in inflammatory bowel disease

    SBC: REELIN THERAPEUTICS, INC.            Topic: 300

    Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    Neurodon LLC proposes to conduct lead optimization and candidate-seeking activities on a novel series of neuroprotective small molecules that shows efficacy in a transgenic model of Alzheimer’s disease (AD). AD is a leading cause of death in the United States, with some estimates ranking it as high as third behind cardiovascular disease and cancer. Despite the enormity of this national public he ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Develop and Commercialize the Bayesian Dose-Response Modeling System and Services

    SBC: KS & ASSOCIATES LLC            Topic: NIEHS

    PROJECT SUMMARY Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation development. One of the most notable improvements in dose-response assessment - a required quantitative step in risk assessment - is the development of benchmark dose (BMD) ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia

    SBC: BRIDGENE BIOSCIENCES INC            Topic: 102

    PROJECT SUMMARY Acute myeloid leukemia (AML), a malignant disease of hematopoietic precursor cells in the bone marrow, is one of the most common cancers in adults accounting for 1% of all cancers. AML is typically diagnosed later in life with individuals 60 and older having a long-term survival rate of merely 5-15%. Cytogenic analysis of the abnormal cells at the time of diagnosis has proven to be ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. A Vaccine for Acute Flaccid Myelitis

    SBC: ALEPH THERAPEUTICS INC            Topic: NIAID

    SUMMARYIn 2014 the United States experienced an outbreak of a previously unknown neurological disease with polio-like symptoms later known as acute flaccid myelitis (AFM). A biennial surge in cases of AFM in 2016 and 2018 has alarmed public health officials. Since then, rapidly accumulating clinical, immunological, and epidemiological evidence has pointed to EV-D68 as the major causative agent of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sensu lato (the Lyme borreliae), which are transmitted by ticks from animal (bird, rodent) reservoirs to human hosts. While a short course of antibiotics is usually effective in eliminating the bacteria a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government